Feline, fibrosarcoma, interleukin-2, ALVAC-IL2, PHN 624
Purpose: To assess the ability of Merial’s Feline Interleukin-2 immunomodulator, Live Canarypox Vector to increase the time to tumor recurrence when administered to cats as an adjunct treatment to surgical excision of fibrosarcoma, and to demonstrate safety when used under field conditions in affected cats.
Tumors located on the head, tail, or distal limbs
Evidence of metastatic disease
Cats with significant co-morbid illness which, in the opinion of the investigator or sponsor, could compromise response to the treatment, interfere with evaluation of its efficacy, or result in the mortality within one year. This includes but is not limited to renal or hepatic failure, history of congestive heart failure or clinical coagulopathy.
Cats having received previous immunotherapy
Cats receiving concurrent chemotherapy ( including corticosteroids) or radiation therapy. Casts must be off of all such therapy for 3 weeks prior to study enrollment
Concurrent medications deemed incongruent with this study. All pre-existing necessary medications should be recorded as concomitant medications
Cats in the care of owners/designee living at a distance from the treatment center that in the opinion of the investigator will make compliance with follow-up incompatible with reasonable travel arrangements
B-cell Lymphoma Vaccine, DNA
Purpose: Evaluation of the efficacy and safety of a vaccine for the extension of post-chemotherapeutic remission times in dogs diagnosed with large B-cell lymphoma. Remission status established 2-4 weeks following of CHOP therapy.
Dogs that exhibit CNS involvement prior to CHOP- based therapy
Dogs with medical illness other than large B-cell lymphoma that, in the opinion of the oncologist could compromise response to the vaccine or interfere with evaluation of its efficacy
Dogs having received previous immunotherapy
Dogs having received long-acting, systemic steroids within 30 days prior to enrollment in the study
Dogs in the care of owners/designee living at a distance from the treatment center that will make compliance with the follow-up incompatible with reasonable travel arrangements.
Canine Osteosarcoma Vaccine, Live Listeria Vector
Written owner informed consent
Client-owned dog- 1 year of age
Body weight: 2kg
Histopathologic diagnosis of osteosarcoma
Amputation of the affected limb complete and followed by 4-6 doses of carboplatin
Performance score of 0 to 1 (0=normal activity; 1=restricted activity, decreased activity from pre-disease status, 2=compromised ambulatory only for vital activities, consistently defecates and urinates in acceptable areas.
Clinically relevant abnormalities on CBC/CS/UA
Evidence of pulmonary metastases on 3-view thoracic radiographs
Any uncontrolled medical condition ( including other concurrent malignancy) that may be disruptive to the intent and objectives of the study
Dog is pregnant or likely to become pregnant
Dog is participating in another study
Dog may not be available for the entire study duration